These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33774750)

  • 21. Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis.
    Ching J; Richards D; Lewis RA; Li Y
    Muscle Nerve; 2021 Oct; 64(4):483-487. PubMed ID: 34076268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
    Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
    J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
    Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
    Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis.
    Pasutharnchat N; Wacharapluesadee S; Hemachudha T
    J Med Assoc Thai; 2012 Mar; 95(3):313-9. PubMed ID: 22550827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to treatment of myasthenia gravis according to clinical subtype.
    Akaishi T; Suzuki Y; Imai T; Tsuda E; Minami N; Nagane Y; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Murai H; Aoki M; Utsugisawa K
    BMC Neurol; 2016 Nov; 16(1):225. PubMed ID: 27855632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
    J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
    Uzawa A; Suzuki S; Kuwabara S; Akamine H; Onishi Y; Yasuda M; Ozawa Y; Kawaguchi N; Kubota T; Takahashi MP; Suzuki Y; Watanabe G; Kimura T; Sugimoto T; Samukawa M; Minami N; Masuda M; Konno S; Nagane Y; Utsugisawa K
    Neurotherapeutics; 2023 Mar; 20(2):518-523. PubMed ID: 36607596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
    Sekine Y; Kawaguchi N; Hamada C; Sekiguchi H; Yasufuku K; Iyoda A; Shibuya K; Fujisawa T
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):908-13. PubMed ID: 16675232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
    Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
    J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of quality of life and activity of daily living status of patients with myasthenia gravis treated with low-dose and high-dose prednisolone.
    Katsuki M; Sugahara H; Kojima Y; Yamashita K; Moriuchi H; Kubota T; Masuda M; Irikura M
    Neuro Endocrinol Lett; 2020 Oct; 41(4):173-178. PubMed ID: 33307652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis.
    Kawaguchi N; Yoshiyama Y; Nemoto Y; Munakata S; Fukutake T; Hattori T
    Curr Med Res Opin; 2004 Aug; 20(8):1269-73. PubMed ID: 15324529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
    Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
    J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.